Recent Developments in PFO Closure
The patent foramen ovale closure market has continued to mature in 2009, with the latest round of developments reported at the 2009 Transcatheter Cardiovascular Therapeutics meeting, recently held in San Francisco. Over 60 presentations related to PFO closure or atrial septal defect closure were presented at TCT this year, more than double the amount of PFO-related talks presented in 2008.
You may also be interested in...
Market & Industry Briefs, November 2012
Brief summaries of recent medtech market and industry developments. This month we cover China’s switch to a centralized billing system, St. Jude Medical’s RESPECT PFO closure trial, FDA’s approval of HeartWare’s LVAD, and end-of-the-year medtech M&A.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.
Patent foramen ovale can be a contributing factor for stroke, chronic migraine, decompression sickness and obstructive sleep apnea. SeptRx Inc.'s percutaneous device for treating PFO is unique in that it mirrors the anatomy of the flat tunnel of tissue that characterizes PFO. Not only is the device itself flat, but its frame laterally stretches the tunnel to keep it flat and bring the tissue surfaces in contact.